NCT01386268View on ClinicalTrials.gov

Kogenate FS Regulatory Post-Marketing Surveillance

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

January 31, 2013

Study Completion Date

August 31, 2013

Conditions

Hemophilia A

Interventions

BIOLOGICAL

Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS

Trial Locations (1)

Unknown

Many Locations